Cohen & Steers vs GCM Grosvenor
CNS and GCMG side by side, both in services allied with the exchange of securities. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CNS and GCMG compare
Cohen & Steers is the larger company, worth 1.3 times as much as GCM Grosvenor ($3.7B against $2.7B).
Cohen & Steers grew revenue faster over the last twelve months (8.6% versus 6.6% for GCM Grosvenor).
Cohen & Steers keeps more of each dollar of sales as profit, with a net margin of 28.2% compared with 8.0% at GCM Grosvenor.
Both pay dividends: Cohen & Steers yields 2.8% and GCM Grosvenor 3.6%.
Cohen & Steers scores higher on the StockData Score (14 against 11 for GCM Grosvenor), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CNS | GCMG |
|---|---|---|
| Size and price | ||
| Market cap | $3.7B | $2.7B |
| Share price | $71.35 | $13.50 |
| Change, 1 year | 7.8% | 17.0% |
| Change, 5 years | −27.5% | 14.8% |
| Beta (5Y) | 0.97 | 0.88 |
| Employees | 411 | 553 |
| StockData Score | ||
| Total score | 14 (better) | 11 |
| Valuation score | 2 (better) | 1 |
| Growth score | 0 | 1 (better) |
| Performance score | 5 (better) | 3 |
| Health score | 5 | 5 |
| Dividend score | 2 (better) | 1 |
| Valuation | ||
| P/E | 21.9× | – |
| P/S | 6.1× | 4.7× (better) |
| P/B | 6.0× (better) | 82.7× |
| EV/EBITDA | 18.0× | 15.7× (better) |
| P/FCF | – | 13.7× |
| FCF yield | – | 7.3% |
| Fair value | $66.63 | $10.68 |
| Margin of safety | −7.1% (better) | −26.4% |
| Growth | ||
| Revenue growth (TTM) | 8.6% (better) | 6.6% |
| Revenue growth, 5Y average | 5.4% (better) | 5.3% |
| Net income growth (TTM) | 2.8% | 36.0% (better) |
| EPS growth (TTM) | 2.2% | – |
| EPS growth, 5Y average | 13.6% | – |
| Profitability | ||
| Operating margin | 32.4% (better) | 27.1% |
| Net margin | 28.2% (better) | 8.0% |
| FCF margin | – | 34.4% |
| Return on equity | 29.2% | 360% (better) |
| Return on invested capital | 30.9% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Altman Z-score | 10.68 (better) | 4.34 |
| Piotroski F-score | 2 | 5 (better) |
| Dividends and buybacks | ||
| Dividend yield | 2.8% | 3.6% (better) |
| Payout ratio | 80.2% | – |
| Years of dividend growth | 3 (better) | 1 |
| Dividend growth, 5Y average | −0.63% | – |
| Buyback yield | 0.52% | 1.8% (better) |
| Shareholder yield | 3.3% | 5.4% (better) |
| Ownership | ||
| Held by institutions | 56.6% | 27.2% |
| Held by insiders | 46.2% | – |
| Insider net buying, 12 months | −$2.5M (better) | −$10.2M |
| Short interest, % of float | 7.3% | – |
Go deeper
- CNS stock overview
- CNS income statement
- CNS valuation and score
- GCMG stock overview
- GCMG income statement
- GCMG valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.